CMPS$6.90
$6.96
Chart
Performance
Key Stats
AI CMPS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCOMPASS Pathways plc is operating in a high-growth thematic area with strong potential, but faces significant financial challenges and an uncertain path to profitability. Technicals show some short-term strength but overall volatility remains a key concern.
Thematic
COMPASS Pathways operates in the innovative and rapidly expanding field of psilocybin therapy for mental health. This aligns with strong secular tailwinds in healthcare innovation and the growing acceptance of novel treatments for mental health conditions.
Fundamental
COMPASS Pathways is an early-stage company with no revenue and significant operating losses. Its balance sheet shows substantial cash, but the path to profitability and sustainable operations is long and uncertain.
Technical
The stock exhibits volatility. While some short-term indicators suggest upward momentum, longer-term trends and recent performance indicate caution. Trading above key moving averages offers some support, but resistance levels are also present.
| Factor | Score |
|---|---|
| Mental Health Treatment Innovation | 90 |
| Regulatory Landscape for Psychedelics | 70 |
| Biotechnology Sector Growth | 65 |
| Competitive Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 80 |
| Cash Flow | 20 |
| Debt Level | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Volume Confirmation | 50 |
| Support & Resistance | 45 |
| Short-term Performance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Improved Earnings Performance
The company has shown positive EPS surprises in the last two reported quarters (Q2 2025: 104.28%, Q1 2025: 0.32%), indicating better-than-expected profitability.
Adequate Cash Position
As of Q4 2024, the company holds $165.081 million in cash equivalents, which provides a buffer against short-term financial needs and supports ongoing operations and development.
Bearish Points (7)
Consistent Net Losses and No Revenue
The company has consistently reported net losses, with a TTM net income of -$99.698 million and zero reported revenue across all periods analyzed (2021-2024), indicating a lack of commercialization and ongoing reliance on funding for operations and research.
High Enterprise Value relative to lack of Revenue
The Enterprise Value as of Q4 2024 is $277.25 million, while the company has zero reported revenue, suggesting a high valuation based on future potential rather than current financial performance.
Calendar
July 2025
31
Next Earnings Date
H: $-0.34
A: $-0.36
L: $-0.37
Profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Seasonals
Price Target
15.90 USD
The 39 analysts offering 1 year price forecasts for CMPS have a max estimate of 45.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Atai Life Sciences is a leading biotechnology company focused on developing mental health treatments. It was the founding shareholder of COMPASS Pathways (CMPS) and maintains a significant stake, with a shared mission to innovate in psychedelic medicine.
Weight: 95
GH Research is a clinical-stage biopharmaceutical company developing therapies for psychiatric and neurological disorders, specifically focusing on 5-MeO-DMT for treatment-resistant depression (TRD), making it a direct competitor to CMPS in the novel psychedelic-assisted therapy space.
Weight: 90
MindMed is a clinical-stage psychedelic medicine biotechnology company developing novel products to treat brain health disorders, including anxiety, depression, and addiction, positioning it as a key peer to CMPS in advancing psychedelic-inspired therapeutics.
Weight: 88
Cybin is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for various mental health conditions, including depression and anxiety, utilizing innovative drug delivery and formulation approaches, similar to CMPS's focus on novel psychedelic treatments.